Monopar Therapeutics Inc. (MNPR)
NASDAQ · Healthcare
Monopar Therapeutics Inc. annual/quarterly shareholder equity history from 2016 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Monopar Therapeutics Inc. shareholder equity for the quarter ending December 31, 2025 were 137.8M, a 150.43% increase year-over-year.
- Monopar Therapeutics Inc. shareholder equity for 2025 were 137.8M, a 150.43% increase from 2024.
- Monopar Therapeutics Inc. shareholder equity for 2024 were 55.0M, a 335.84% increase from 2019.
- Monopar Therapeutics Inc. shareholder equity for 2019 were 12.6M, a 82.53% increase from 2018.
- Monopar Therapeutics Inc. shareholder equity for 2018 were 6.9M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Monopar Therapeutics Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $138 |
| 2024 | $55 |
| 2019 | $13 |
| 2018 | $7 |
| 2017 | $10 |
| 2016 | $3 |
| Monopar Therapeutics Inc. Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2025-12-31 | $138 |
| 2024-12-31 | $55 |
| 2019-12-31 | $13 |
| 2018-12-31 | $7 |
| 2017-12-31 | $10 |
| 2016-12-31 | $3 |
Monopar Therapeutics Inc. Shareholder Equity — FAQ
Monopar Therapeutics Inc. (MNPR) shareholder equity over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see MNPR's shareholder equity history?
The chart and table above show Monopar Therapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.